CDC Logo Tuberculosis Information CD-ROM   Image of people
jump over main navigation bar to content area
TB Guidelines
Surveillance Reports
Slide Sets
TB-Related MMWRs and Reports
Education/Training Materials
Ordering Information


U.S. Department of Health and Human Services


Guide for Primary Health Care Providers: Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection


ATS/CDC/IDSA. Treatment of tuberculosis. MMWR 2003;52 (No. RR-11).

CDC. Targeted tuberculin testing and treatment of latent TB infection. MMWR 2000;49 (No. RR-6).

CDC. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for the treatment of latent tuberculosis infection—United States, 2003. MMWR 2003;52(31):735-9.

CDC. Guidelines for using the Quantiferon®-TB test for diagnosing latent Mycobacterium tuberculosis infection. MMWR 2003;52(RR02):15-18.

CDC. Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR 2004;53(2):37.

CDC. Tuberculosis associated with blocking agents against tumor necrosis factor - alpha - California, 2002–2003. MMWR 2004; 53 (No. 30).

CDC. Guidelines for preventing opportunistic infections among HIV-infected persons—2002: Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR 2002;51(RR-8).


Released October 2008
Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination -

Please send comments/suggestions/requests to:, or to
CDC/Division of Tuberculosis Elimination
Communications, Education, and Behavioral Studies Branch
1600 Clifton Rd., NE - Mailstop E-10, Atlanta, GA 30333